摘要
In the recent issue of Asian Journal of Andrology,Ni et al.1 explore a therapeutic reflex that we as clinicians have developed over the years when treating patients with metastatic castration-resistant prostate cancer(mCRPC)with abiraterone acetate(AA).With the first signs of progression,usually,this is a rising prostate-specific antigen(PSA)level;we often continue AA but switch corticoid from prednisone to 0.5 mg of dexamethasone daily.In a subset of patients,this causes a temporary PSA decline lasting several months to occasionally over a year.It is a very cheap,well-tolerated,and safe option,although evidence for a long-term oncological benefit,such as an overall survival(OS)increase,is lacking.
